GPCRs

GPCRs
#Drug discovery #GPCRs #Oncology

eBook: Insights into GPCR drug discovery & development 

G protein-coupled receptors (GPCRs) form one of the largest drug target families, with 516 approved drugs targeting GPCRs. They play a central role in cellular signalling pathways, including neurotransmission, immune response and metabolic regulation, making them key targets for therapeutic intervention. Currently approved drugs act on 121 GPCR… Read More

#News

#GPCRs #Nuclera

Nuclera launches GPCR-focused nanodisc panel 

Nuclera has announced the launched of a nanodisc panel focused on supporting G-Protein Coupled Receptors (GPCR) research and streamlining membrane protein production.  Building on the eProtein Discovery membrane protein workflow capabilities, the nanodisc panel allows membrane protein scientists focusing on GPCR research to identify optimal membrane environments and increase production of challenging therapeutic targets, GPCRs, producing active… Read More

#News

T cells attack a cancer cell
#Anti-inflammatory #Canada #GPCRs #Immuno-oncology

Kainova secures funding to develop GPCR-targeting therapies 

Biopharmaceutical company Kainova Therapeutics has secured $32 million CAD (US $24 million) to accelerate the development of immuno-oncology and inflammation therapies.  This financing round was led by Investissement Québec, with funds set to support Kainova’s advancement of GPCR-targeting therapies.  The company’s lead asset DT-7012, a Treg-depleting anti-CCR8 antibody,… Read More

#Business & Investment #News

#Domain Therapeutics #GPCRs #New appointment #Oncology

New Domain chief medical officer to advance GPCR pipeline

Domain Therapeutics has announced the appointment of Dr Jean-Marie Cuillerot as Chief Medical Officer (CMO).  Dr Cuillerot brings pharmaceutical and biotech experience, with a track record in leading successful clinical development programmes and regulatory strategy.   Earlier in his career, Dr Cuillerot served as the… Read More

#Business & Investment #News

#AI #Antibody #Drug discovery #GPCRs

Abalone Bio talks opportunities for GPCR targets  

DDW Editor Reece Armstrong speaks to Richard Yu, CEO and Co-Founder of Abalone Bio about the company’s efforts to develop antibody antagonists for GPCR targets.  RA: What have been the biggest challenges of developing GPCR therapeutics?  RY: The number one challenge is specificity, and it plays out in… Read More

#Exclusive Content

Scientist working with multi well plate for cell culture in the lab
#Antibody drug conjugate (ADC) #Drug discovery #GPCRs #Reagents #Revvity

Revvity launches new reagents for GPCR research

Revvity has launched pHSense reagents, designed to advance internalisation studies in drug discovery.   pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs).  Developed for use with standard plate readers, pHSense reagents combine a… Read More

#News

Weight loss concept
#GLP-1 #GPCRs #Nxera Pharma #Obesity #Weight loss

Nxera unveils obesity and chronic weight management pipeline

Biopharmaceutical company Nxera Pharma has launched a broad new pipeline strategically focused on advancing therapies for obesity and associated metabolic disorders.  Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline… Read More

#News

#Cardiometabolic diseases #Collaboration #GPCRs #Novo Nordisk #Obesity

Novo Nordisk and Deep Apple announce collaboration

Novo Nordisk and Deep Apple Therapeutics have announced a research collaboration and exclusive worldwide license agreement to discover and develop oral small molecule therapeutics.  The new drugs will be directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity.  Under the terms of… Read More

#Business & Investment #News

#GPCRs #High throughput screening #Medicinal chemistry #Whitepaper

Whitepaper: Understand GPCR second messenger data analysis

A new Whitepaper is now available from Revvity entitled ‘Guidelines and recommendations for analyzing and interpreting GPCR second messenger data‘. The Whitepaper offers expert guidelines for analysing GPCR second messenger data: Detailed comparison of four data analysis methods Practical case studies for method application Specific insights for high-throughput… Read More

#News

#GPCRs #High throughput screening #Medicinal chemistry

Unlock expert insights on GPCR second messenger data analysis

This Whitepaper offers expert guidelines for analysing GPCR second messenger data: Detailed comparison of four data analysis methods Practical case studies for method application Specific insights for high-throughput screening and medicinal chemistry… Read More

#Resources

Researcher loads DNA samples for PCR analysis
#Acute inflammatory conditions #Domain Therapeutics #GPCRs #Neuroinflammation

PAR2-targeting drug has “game-changing potential”

Domain Therapeutics has announced plans to progress DT-9046, a candidate it says has game-changing potential in multiple inflammatory disease markets, including atopic dermatitis (AD), inflammatory bowel disease (IBD), arthritis but also neuroinflammation including migraine.  PAR2 has emerged as a pivotal therapeutic in inflammatory diseases due to its… Read More

#News

#Acute inflammatory conditions #Financing #GPCRs #Maxion Therapeutics #Therapeutic Antibodies

Maxion Therapeutics raises $72m to advance KnotBody pipeline

Maxion Therapeutics has raised $72 million in an oversubscribed Series A Financing to advance its antibody-based KnotBody drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases.  The financing was led by General Catalyst with additional investment from new investors, British Patient Capital, Solasta Ventures and… Read More

#Business & Investment #News

#Acute inflammatory conditions #Fibrosis #Fibrotic disease #GPCRs #Oncology

Is GPR68 a potential master switch for fibrotic and inflammatory diseases?

Simona E Carbone, Michelle P Papadimitriou and Darren J Kelly, discuss why GPR68 has been considered an attractive target for cancer therapy – albeit difficult to drug – and highlight its exciting potential in the development of drugs to treat a range of inflammatory and fibrotic diseases. GPR68, or OGR1,… Read More

#Exclusive Content

Neurons
#Cell therapy #GPCRs #Neurology #Neuroscience #Stanford University

New ‘PAGER’ technology could transform cell therapies

Researchers at Stanford University have built a new synthetic receptor with broad potential to programme cell activity, including immune response and neurological signalling.  Detailed in a paper published in Nature, the new synthetic receptor accommodates a broader range of inputs and… Read More

#Editor's Choice #News

Antibodies
#Antiverse #Artificial intelligence (AI) #Collaboration #GPCRs #Nxera Pharma #Therapeutic Antibodies

Partners set out to design GPCR-targeted antibodies using AI

A new multi-target partnership aims meet unmet need by designing antibodies for G-protein coupled receptors (GPCRs). The collaboration will combine Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-specific libraries’, with Nxera’s NxWave platform for GPCR target selection, validation and structural determination. Read More

#Business & Investment #News

#Confo Therapeutics #Endocrinology #Funding #GPCRs #Metabolomics

€1.6m grant supports drug discovery in metabolic diseases

Confo Therapeutics has been awarded a €1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The two-year grant will be used to expand Confo’s R&D efforts in the discovery of new medicines targeting Class B G protein-coupled receptors (GPCRs) using its patent-protected technology platform. Read More

#News